Britain to allow infecting volunteers in trials for Covid-19 vaccines

Britain said on Tuesday it would back “human challenge” trials, where young and healthy volunteers are deliberately infected with Covid-19, to accelerate the development of vaccines for the disease.

The government said it would invest 33.6 million pounds ($43.5 million) in the studies in partnership with Imperial College London, laboratory and trial services company hVIVO and the Royal Free London NHS Foundation Trust.

If approved by regulators and an ethics committee, the studies would start in January with results expected by May 2021, the government said.

Open Orphan (LON:ORPH) was founded in 2017, with the goal of rapidly building Europe’s leading pharma services company by a management team with extensive industry and financial expertise. The company comprises of two commercial specialist CRO services businesses (Venn Life Sciences and hVIVO) and is also developing a genomics data platform business (Genomic Health Data). 

Click to view all articles for the EPIC:
Or click to view the full company profile:
Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Open Orphan PLC

More articles like this

Open Orphan Plc

How human challenge trials can accelerate vaccine development

Human challenge studies provide more valuable information than animal challenge studies, which produce results that must be extrapolated in order to determine the impact on humans. They also allow for trials on a small participant pool that faces

Open Orphan Plc

Considerations on Manufacturing Challenge Agents webinar

Open Orphan (LON:ORPH) was founded in 2017, with the goal of rapidly building Europe’s leading pharma services company by a management team with extensive industry and financial expertise. The company comprises of two commercial specialist CRO services businesses

Open Orphan Plc

Global leader in Human Challenge vaccine development

Open Orphan (LON:ORPH) was founded in 2017, with the goal of rapidly building Europe’s leading pharma services company by a management team with extensive industry and financial expertise. The company comprises of two commercial specialist CRO services businesses

Open Orphan Plc

Open Orphan could realise £20 million in first non-core asset IPO

Co-founder Cathal Friel has indicated that a series of spinouts could unlock £750 million for shareholders in the Dublin-based pharma company. Open Orphan, the Dublin-listed pharmaceutical services company run by Cathal Friel, will launch an initial public offering